Details of the Drug Combinations

General Information of This Drug (ID: DMQUSBT)

• Drug Name: Daunorubicin (DMQUSBT)
• Synonyms: daunorubicin; Daunomycin; 20830-81-3; Rubidomycin; Cerubidine; Daunorubicine; Acetyladriamycin; Leukaemomycin C; Daunorubicinum; Daunarubicinum; Daunorrubicina; Daunamycin; Cerubidin; DaunoXome; Rubomycin C; (+)-Daunomycin; Daunoblastin; Anthracyline; Rubomycin; Daunorubicinum [INN-Latin]; RP 13057; Daunorubicin [INN:BAN]; RCRA waste no U059; FI6339; NSC-82151; DAUNORUBICIN HCL; DaunoXome (TN); UNII-ZS7284E0ZP; CCRIS 914; ZS7284E0ZP; CHEBI:41977; HSDB 5095; C27H29NO10; NCI-C04693; EINECS 244-069-7; Ondena; NSC 83142; Acetyladriamycin; Daunoblastine; Antibiotics from Streptomyces coeruleorubidus; DM1; FI 6339; Dauno-Rubidomycine; Daunorubicin (INN); Daunorubicin (liposomal); Daunorubicin, Hydrochloride; VS-103; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside; (7S,9R)-9-Acetyl-7-[(2S,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S-cis)-8-Acetyl-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyrannosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-napthacenedione; (8S-cis)-8-Acetyl-10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; Anthracycline

Indication

Acute monocytic leukemia; ICD 11: N.A.; Status: Approved [1]; Acute myelogenous leukaemia; ICD 11: 2A41; Status: Approved [1]; Acute myeloid leukaemia; ICD 11: 2A60; Status: Approved [2]; Kaposi sarcoma; ICD 11: 2B57; Status: Approved [3]; Leukemia; ICD 11: N.A.; Status: Approved [1]; Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 2 [4]

• Therapeutic Class: Anticancer Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Daunorubicin + Panobinostat	DC5DIHB	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[5]

23 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Daunorubicin + PF-04449913	DCD4PRD	PF-04449913	Acute Myeloid Leukemia	[6]
Daunorubicin + Cytarabine	DCH5YZL	Cytarabine	Leukemia	[7]
Daunorubicin + Cytarabine	DCNMO43	Cytarabine	Acute Myeloid Leukemia	[8]
Daunorubicin + Dasatinib	DCS4SCA	Dasatinib	Acute Myeloid Leukemia (AML)	[9]
Daunorubicin + Gilteritinib	DCCPFO9	Gilteritinib	Acute Myeloid Leukemia With FLT3/ITD Mutation	[10]
Flavopiridol + Daunorubicin	DCPZJ07	Flavopiridol	Acute Myeloid Leukemia	[11]
GS-9973 + Daunorubicin	DCKKHBI	GS-9973	Hematologic Malignancy	[12]
GS-9973 + Daunorubicin	DCKP0X6	GS-9973	Acute Myeloid Leukemia	[13]
Idarubicin + Daunorubicin	DCVBHJ7	Idarubicin	Acute Myeloid Leukemia	[14]
Panobinostat + Daunorubicin	DCRNZRX	Panobinostat	Acute Myeloid Leukemia	[15]
RG7388 + Daunorubicin	DC3ZDJY	RG7388	Acute Myeloid Leukemia	[16]
Venetoclax + Daunorubicin	DCHOPE8	Venetoclax	Acute Myeloid Leukemia	[17]
Daunorubicin + Azacitidine	DCKWNXK	Azacitidine	MDS	[18]
Daunorubicin + Cytarabine	DCU9GCL	Cytarabine	Newly Diagnosed AML With FLT3 Activating Mutations	[19]
Daunorubicin + Gilteritinib	DCXW8J5	Gilteritinib	Acute Myeloid Leukemia	[20]
Midostaurin + Daunorubicin	DCGGLSN	Midostaurin	Acute Myeloid Leukemia	[20]
Mitoxantrone + Daunorubicin	DCUTFEA	Mitoxantrone	Acute Myeloid Leukemia (AML)	[21]
Dexamethasone + Daunorubicin	DC5OJER	Dexamethasone	Leukemia	[22]
Docetaxel + Daunorubicin	DCCIJAA	Docetaxel	Endometrial Neoplasms	[23]
Etoposide + Daunorubicin	DCO9Y73	Etoposide	Acute Myeloid Leukemia	[24]
Idarubicin + Daunorubicin	DCK77A1	Idarubicin	Acute Myeloid Leukemia (AML)	[25]
Idarubicin + Daunorubicin	DC5EV11	Idarubicin	Acute Myeloid Leukemia (AML)	[25]
Midostaurin + Daunorubicin	DCAV7KA	Midostaurin	Acute Myeloid Leukemia With FLT3/ITD Mutation	[26]

References

• [1] Daunorubicin FDA Label
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7063).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer. 2004 Mar;40(4):536-42.
• [5] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [6] ClinicalTrials.gov (NCT01546038) A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
• [7] ClinicalTrials.gov (NCT00085709) S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
• [8] ClinicalTrials.gov (NCT00788892) Trial of CPX-351 in Newly Diagnosed Elderly AML Patients
• [9] ClinicalTrials.gov (NCT00850382) Dasatinib (Sprycel? in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
• [10] ClinicalTrials.gov (NCT05024552) Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML
• [11] ClinicalTrials.gov (NCT03298984) Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
• [12] ClinicalTrials.gov (NCT03135028) Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
• [13] ClinicalTrials.gov (NCT02343939) Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)
• [14] ClinicalTrials.gov (NCT02236013) A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
• [15] ClinicalTrials.gov (NCT01463046) Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
• [16] ClinicalTrials.gov (NCT03850535) A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
• [17] ClinicalTrials.gov (NCT05342584) Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS
• [18] ClinicalTrials.gov (NCT04061239) Comparison of Therapies Before Stem Cell Transplantation in Patients With Higher Risk MDS and Oligoblastic AML
• [19] ClinicalTrials.gov (NCT02283177) A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
• [20] ClinicalTrials.gov (NCT03836209) Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia
• [21] ClinicalTrials.gov (NCT02198482) Trial of Intensive Chemotherapy With or Without Volasertib in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
• [22] ClinicalTrials.gov (NCT00651261) Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
• [23] ClinicalTrials.gov (NCT03517449) Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
• [24] ClinicalTrials.gov (NCT00703820) Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
• [25] ClinicalTrials.gov (NCT02013648) Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel?
• [26] ClinicalTrials.gov (NCT04174612) AML Patients Bearing FLT3 Mutations Based on Peripheral Blast Clearance